|
Daily Medical Update
Aortic stenosis
Saturday, June 20, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
The New England journal of medicine (2026) - Randomized Controlled Trial
Key Findings
- The primary composite of operative mortality or cardiovascular death occurred in 3% with early surgery versus 24% with conservative care over 10 years (HR 0.10; 95% CI 0.02-0.43).
- All-cause death occurred in 15% of the early-surgery group versus 32% of the conservative-care group (HR 0.42; 95% CI 0.21-0.86).
📋 Practice Implication: For asymptomatic patients with very severe aortic stenosis, referral for valve replacement should be discussed before symptom onset rather than waiting for clinical deterioration.
|
The American journal of medicine (2026) - Meta-Analysis
Key Findings
- Across 13 studies, early aortic valve replacement was associated with lower all-cause mortality (RR 0.51), cardiovascular mortality (RR 0.45), and heart failure hospitalization (RR 0.40) versus conservative management.
- Among asymptomatic severe aortic stenosis cohorts followed for about 4 to 6 years, 44% developed symptoms and 33% of conservatively managed patients who remained asymptomatic died.
📋 Practice Implication: Structured surveillance alone is inadequate for many asymptomatic severe cases, so Heart Team review should occur early when operative risk is acceptable and left ventricular function is still preserved.
|
Anaesthesia (2025) - Meta-Analysis
Key Findings
- Estimated all-cause mortality after non-cardiac surgery was 3.8% for any aortic stenosis and 9.6% for severe aortic stenosis.
- Compared with patients without aortic stenosis, aortic stenosis was associated with higher mortality (RR 1.58), myocardial infarction (RR 1.79), and heart failure (RR 2.06) after non-cardiac surgery.
📋 Practice Implication: Preoperative planning for non-cardiac surgery should treat severe aortic stenosis as a major perioperative risk modifier and prompt tighter anesthesia, cardiology, and procedural coordination.
|
Heart & lung : the journal of critical care (2025) - Meta-Analysis
Key Findings
- In patients with concomitant aortic stenosis and coronary artery disease, PCI plus TAVR was associated with higher all-cause mortality at 48 months than CABG plus SAVR (HR 1.29; 95% CI 1.23-1.35).
- PCI plus TAVR showed lower perioperative complications, but myocardial infarction within 30 days was higher than with CABG plus SAVR (RR 1.61; 95% CI 1.08-2.39).
📋 Practice Implication: When coronary disease requires revascularization, less invasive transcatheter strategies should be weighed against a possible longer-term survival penalty, especially in patients who are reasonable surgical candidates.
|
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2026) - Meta-Analysis
Key Findings
- Post-TAVR renin-angiotensin system inhibitor use carried a 79.4% probability of a clinically relevant reduction in all-cause mortality and a 99.5% probability of a clinically relevant reduction in cardiovascular mortality.
- The analysis also found a 54% probability of a clinically relevant reduction in heart failure hospitalization, with only a negligible 2.26% probability of reducing myocardial infarction.
📋 Practice Implication: After technically successful TAVR, clinicians should revisit guideline-directed medical therapy rather than assuming valve replacement alone has resolved ongoing remodeling and heart failure risk.
|
|
💡
Summary
Recent aortic stenosis literature continues to favor earlier intervention in selected asymptomatic severe disease, with randomized and pooled evidence showing lower cardiovascular death, all-cause mortality, and heart failure hospitalization versus watchful waiting. Newer data also sharpen perioperative risk estimates for non-cardiac surgery, clarify tradeoffs between transcatheter and surgical strategies when coronary disease coexists, and suggest that post-TAVR renin-angiotensin system inhibition may improve downstream outcomes. Together, these studies support more proactive Heart Team decision-making before surgery, at the time of valve selection, and during longitudinal post-procedural management.
|
|